The Efficacy Comparison Of FLAG And FLAG Combined Anthracycline Regimen On R/R AML:A Mata-analysis

Objective:To evaluate the efficacy,adverse reactions and prognosis of FLAG and FLAG combined anthracycline on relapsed or refractory acute myeloid leukemia(R/R AML).Method:Clinical case control trials abaut FLAG and FLAG combined anthracycline in the treatment of R/R AML were collected,through retrieving pubmed,SCI,Cochrane,Elsevier,Embase,Ovid,FMJS,CNKI,CBM on line,from database building to June 2017.Two researchers screened,extracted materials and evaluated literature quality according the inclusion criteria independently.The literature datas were taken RevMan5.3 software to do Meta analysis.Results:Eleven trials involving 998 patients were retrieved.Meta-analysis results suggested that the CR and total effective rates of FLAG combined anthracycline was higher than FLAG group[RR=1.24,95%CI(1.09,1.42),P=0.001;RR=1.40,95%CI(1.25,1.57),P<0.00001],and Serum transaminase increase rate was lower than FLAG group[RR=0.28,95%CI(0.14,0.57),P=0.0004],but adverse reactions rate such as mouth ulcer,nausea and vomiting,infection and prognosis were no difference between two groups.Conclusions:Based on the present review results,the CR and total effective rates of FLAG combined anthracycline was higher than FLAG group,but there was no significant increase in the incidence of adverse reactions,and there was no statistically significant difference in prognosis.